Current recommendations and recent progress in endometrial cancer-Reference-Cited by-同舟云学术

Current recommendations and recent progress in endometrial cancer

Published:2019-05-10 Issue: Volume: Page:
ISSN:0007-9235
Container-title:CA: A Cancer Journal for Clinicians
language:en
Short-container-title:CA A Cancer J Clin

Author:

Brooks Rebecca A.¹²,Fleming Gini F.³,Lastra Ricardo R.⁴,Lee Nita K.⁵,Moroney John W.⁶,Son Christina H.⁷,Tatebe Ken⁸,Veneris Jennifer L.⁹

Affiliation:

1. Associate Professor, Department of Gynecologic Oncology The University of Chicago Chicago IL

2. Dr. Brooks is now the Associate Professor and Chief of the Division of Gynecologic Oncology University of California Davis School of Medicine Davis CA

3. Professor of Medicine and Director, Medical Oncology Breast Program, Department of Medical Oncology The University of Chicago Chicago IL

4. Assistant Professor, Department of Pathology The University of Chicago Chicago IL

5. Assistant Professor of Obstetrics and Gynecology, Department of Gynecologic Oncology The University of Chicago Chicago IL

6. Associate Professor of Obstetrics and Gynecology, Department of Gynecologic Oncology The University of Chicago Chicago IL

7. Assistant Professor, Department of Radiation and Cellular Oncology The University of Chicago Chicago IL

8. Resident, Department of Radiation and Cellular Oncology The University of Chicago Chicago IL

9. Instructor of Medicine, Division of Gynecologic Oncology Dana‐Farber Cancer Institute and Harvard Medical School Boston MA

Publisher

Wiley

Subject

Oncology,Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.3322/caac.21561

Reference138 articles.

1. Hysterectomy-corrected rates of endometrial cancer among women younger than age 50 in the United States

2. Cancer statistics, 2013

3. Cancer statistics, 2018

4. Integrated genomic characterization of endometrial carcinoma

5. Surveillance Epidemiology and End Results (SEER) Program Cancer Stat Facts: Uterine Cancer.cancer.net/cancer-types/uterine-cancer/statistics. Accessed January 20 2019.

Cited by 351 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy;Gynecologic Oncology;2024-03

2. Sentinel lymph node biopsy in endometrial cancer: When, how and in which patients;European Journal of Surgical Oncology;2024-03

3. FKBP38 suppresses endometrial cancer cell proliferation and metastasis by inhibiting the mTOR pathway;Archives of Biochemistry and Biophysics;2024-02

4. Pathogenetic characteristics of endometrioid adenocarcinoma of uterus at present stage;Medical alphabet;2024-01-17

5. Fanconi anemia complementation group D2 promotes sensitivity of endometrial cancer cells to chemotherapeutic agents by inhibiting the ferroptosis pathway;BMC Women's Health;2024-01-13